Enclomiphene and gynaecomastia is a clinically important concern for men considering this unlicensed selective oestrogen receptor modulator (SERM) for secondary hypogonadism. By stimulating the pituitary to increase LH and FSH output, enclomiphene raises endogenous testosterone — but also indirectly elevates oestradiol through aromatisation. This hormonal shift can, in susceptible individuals, disturb the androgen-to-oestrogen balance at breast tissue level. Understanding the mechanism, risk factors, warning signs, and appropriate clinical response is essential for anyone using or prescribing enclomiphene in the UK, where it remains an unlicensed medicine.

How Enclomiphene Works and Its Effects on Hormone Levels

Enclomiphene blocks oestrogen receptors at the hypothalamus and pituitary, increasing LH and FSH secretion and stimulating endogenous testosterone production, which can also raise oestradiol via aromatisation.

Enclomiphene is a non-steroidal selective oestrogen receptor modulator (SERM) and the trans-isomer of clomiphene citrate. It acts predominantly as an oestrogen receptor antagonist at the hypothalamus and pituitary gland, disrupting the normal negative feedback that oestrogen exerts on gonadotrophin-releasing hormone (GnRH) release. This blockade prompts the pituitary to secrete higher levels of luteinising hormone (LH) and follicle-stimulating hormone (FSH), which in turn stimulate the testes to produce more testosterone.

Because enclomiphene stimulates endogenous testosterone production rather than replacing it exogenously, it has been explored as a potential treatment for secondary hypogonadism in men — particularly as an alternative to testosterone replacement therapy (TRT). Unlike TRT, it preserves testicular function and fertility. However, it is important to note that enclomiphene has no marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) and is not approved by the European Medicines Agency (EMA) or the US Food and Drug Administration (FDA). Any use in the UK is therefore as an unlicensed medicine, which should only be initiated and supervised by a clinician with specialist experience in male hormonal health, in accordance with MHRA guidance on the supply of unlicensed medicinal products ('specials').

The hormonal changes enclomiphene induces are not entirely straightforward. As testosterone levels rise, a proportion is naturally converted to oestradiol via the enzyme aromatase — a process known as aromatisation. This means that alongside elevated testosterone, circulating oestrogen levels may also increase. The balance between testosterone and oestrogen — rather than the absolute level of either hormone alone — is a key determinant of breast tissue changes in men, and is central to understanding the potential risk of gynaecomastia.

The Link Between Enclomiphene and Gynaecomastia

Enclomiphene can theoretically cause gynaecomastia if oestradiol rises disproportionately relative to testosterone; robust trial evidence is limited, but breast tenderness and tissue changes have been reported in clinical practice.

Gynaecomastia refers to the benign enlargement of glandular breast tissue in males, caused by an imbalance between oestrogenic and androgenic activity at breast tissue receptors. Given that enclomiphene raises both testosterone and, indirectly, oestradiol through aromatisation, the question of whether enclomiphene can cause gynaecomastia is clinically relevant.

There is currently no robust, large-scale clinical trial data definitively establishing enclomiphene as a direct cause of gynaecomastia. However, its pharmacological mechanism creates conditions under which gynaecomastia could theoretically develop — particularly if oestradiol rises disproportionately relative to testosterone, or if an individual has heightened aromatase activity. Some case reports and accounts from clinical practice suggest that breast tenderness or mild tissue changes have been reported in a subset of men using enclomiphene, though this is not universally observed.

Clomiphene citrate — the parent compound from which enclomiphene is derived — has been reported in association with gynaecomastia in men, partly because its cis-isomer (zuclomiphene) has oestrogenic properties. This is reflected in the clomifene citrate Summary of Product Characteristics (SmPC) available via the Electronic Medicines Compendium (EMC) and the BNF. Enclomiphene, as the isolated trans-isomer, is considered to have a more favourable hormonal profile with less oestrogenic activity; however, there is no regulatory confirmation that it is entirely free from this risk, and the evidence base remains limited.

Monitoring oestradiol levels during treatment is considered reasonable clinical practice in specialist care to identify hormonal imbalance early, though there is no specific UK guideline mandating this for enclomiphene. Any such monitoring and dose decisions should be made by the supervising specialist.

Risk Factors That May Increase the Likelihood of Breast Tissue Changes

High body fat, elevated baseline oestradiol, concurrent gynaecomastia-causing medicines, and liver or kidney disease are key factors that increase the risk of breast tissue changes during enclomiphene treatment.

Not all men taking enclomiphene will develop gynaecomastia, and several individual risk factors may increase susceptibility. Understanding these factors can help clinicians and patients make more informed decisions about treatment and monitoring.

Key risk factors include:

• Elevated baseline oestradiol: Men who already have higher circulating oestrogen levels before starting treatment may be at greater risk of breast tissue stimulation.

• High body fat percentage: Adipose tissue is rich in aromatase enzyme, meaning that men with obesity or a high body mass index (BMI) convert more testosterone to oestradiol, increasing the oestrogen-to-androgen ratio.

• Genetic predisposition: Variations in aromatase gene expression (CYP19A1) can theoretically increase conversion of androgens to oestrogens in some individuals, though genetic testing for this is not part of routine UK clinical practice.

• Concurrent medicines: A number of medicines are recognised causes of gynaecomastia in their own right. These include spironolactone, finasteride, dutasteride, anti-androgens, ketoconazole, antipsychotics, SSRIs, digoxin, cimetidine, and anabolic steroids, among others (see NICE CKS: Gynaecomastia for a fuller list). Men taking any of these alongside enclomiphene may face an additive risk.

• Liver or kidney disease: These conditions can impair hormone metabolism, leading to oestrogen accumulation.

• Pre-existing gynaecomastia: Men with a prior history of breast tissue enlargement may be more susceptible to further changes.

Age is also relevant. Older men tend to have naturally higher oestradiol-to-testosterone ratios due to declining testicular function and increased adiposity, which may compound the hormonal effects of enclomiphene.

A thorough baseline assessment is advisable before initiating treatment, particularly in individuals with one or more of these risk factors. This should include serum testosterone, oestradiol, LH, FSH, prolactin, thyroid function tests (TFTs), liver function tests (LFTs), and human chorionic gonadotrophin (hCG) where clinically indicated, alongside a testicular examination.

Recognising the Signs of Gynaecomastia During Treatment

Gynaecomastia typically presents as breast tenderness or a firm, rubbery subareolar lump; red-flag features such as a hard irregular mass or bloody nipple discharge require urgent clinical assessment.

Early recognition of gynaecomastia is important for timely management and to prevent progression to more established breast tissue changes, which can be harder to reverse. Men taking enclomiphene should be aware of the signs and symptoms that may indicate the development of breast tissue enlargement.

Common signs of gynaecomastia include:

• Breast tenderness or sensitivity: Often the earliest symptom, this may present as a dull ache or heightened sensitivity around the nipple area.

• A firm, rubbery lump beneath the nipple: This represents glandular tissue proliferation and is distinct from the softer, fatty tissue associated with pseudogynaecomastia (lipomastia).

• Visible swelling or enlargement of one or both breasts: This may be unilateral or bilateral and can vary in degree.

• Nipple discharge: Though less common, this warrants prompt medical evaluation to exclude other causes.

It is important to distinguish true gynaecomastia — which involves glandular tissue — from pseudogynaecomastia, which is simply fat deposition in the chest area and is not hormonally driven in the same way. True gynaecomastia typically presents as a palpable, firm disc of tissue centred beneath the areola.

Red-flag features requiring urgent assessment include:

• A hard, irregular, or rapidly enlarging breast mass

• Unilateral nipple inversion, eczematous nipple changes, or ulceration

• Skin tethering or dimpling

• Bloody or spontaneous nipple discharge

• Axillary lymphadenopathy

• Systemic symptoms such as unexplained weight loss or fatigue

These features may indicate a more serious underlying cause, including the rare possibility of male breast cancer, and should prompt urgent referral. NICE guideline NG12 (Suspected Cancer: Recognition and Referral) sets out criteria for two-week-wait referrals, including men aged 50 or over with nipple changes or discharge, and anyone with suspicious clinical features.

Symptoms can develop gradually over weeks to months of treatment. Men should be encouraged to report any changes promptly to their prescribing clinician. Early-stage gynaecomastia, particularly within the first few months, is more likely to resolve with dose adjustment or treatment modification than long-standing, fibrotic breast tissue changes.

What to Do If You Notice Breast Changes While Taking Enclomiphene

Contact your prescribing doctor promptly, request a hormonal assessment including testosterone and oestradiol, and do not alter your treatment without medical guidance; red-flag features warrant urgent NICE NG12 two-week-wait referral.

If you notice any breast tenderness, swelling, or a palpable lump whilst taking enclomiphene, it is important not to ignore these changes. Prompt action can prevent progression and allow for appropriate clinical assessment.

Steps to take if you experience breast changes:

• Contact your prescribing doctor or GP promptly: Inform them of the nature, onset, and severity of your symptoms. In many cases, stopping or reducing the dose of the suspected causative medicine is an appropriate first step, and your clinician will advise whether this applies to you. Do not make changes to your treatment without medical guidance.

• Request a hormonal and clinical assessment: Your clinician should check serum testosterone, oestradiol, LH, FSH, prolactin, TFTs, LFTs, and hCG where indicated, alongside a testicular examination. This helps identify any underlying hormonal imbalance or alternative cause.

• Discuss management options with your specialist: If oestradiol levels are elevated, your clinician may consider reducing or stopping enclomiphene. In some cases, specialist-led treatments such as tamoxifen (for painful early gynaecomastia) may be considered. The addition of an aromatase inhibitor (such as anastrozole) is off-label in this context and should only be considered under specialist supervision after careful assessment of risks and benefits.

• Seek further investigation if needed: If a lump is identified, your GP may refer you for breast ultrasound or mammography to confirm the diagnosis and exclude other pathology. Any new breast lump in a male patient should be assessed clinically.

• Urgent referral if red flags are present: If any of the red-flag features described in the previous section are present, your GP should refer you urgently under the NICE NG12 two-week-wait pathway for suspected cancer. Reassurance should only follow thorough evaluation.

In most cases, gynaecomastia associated with hormonal treatment is benign and manageable when identified early. The NHS recommends that men with unexplained breast lumps seek prompt medical review (see NHS: Gynaecomastia — when to see a GP).

Regulatory Status and Clinical Guidance on Enclomiphene Safety in the UK

Enclomiphene is unlicensed in the UK with no MHRA, EMA, or FDA approval; its use must follow MHRA unlicensed medicines guidance under specialist supervision, and adverse effects should be reported via the Yellow Card scheme.

Experiencing these side effects? Our pharmacists can help you navigate them →

Enclomiphene occupies an important regulatory position in the United Kingdom that patients and clinicians should understand clearly. Enclomiphene has no marketing authorisation from the MHRA and is not approved by the EMA or the FDA. It is therefore an unlicensed medicine in the UK. Any supply must follow MHRA guidance on unlicensed medicinal products ('specials'), which permits use only where a licensed alternative is not suitable for an individual patient and under the responsibility of a prescribing clinician. In practice, enclomiphene may be obtained via MHRA-licensed specials manufacturers or as an imported unlicensed medicine through appropriate routes — not via standard community pharmacy dispensing.

NICE does not currently provide specific guidance endorsing enclomiphene for male hypogonadism, and its use falls outside standard NHS prescribing pathways. Men considering enclomiphene should be aware that they are using a medicine outside established regulatory frameworks, and should ensure they are under the supervision of a qualified clinician with experience in male hormonal health.

Key safety considerations drawn from clinical literature and the clomifene citrate SmPC (EMC) and BNF — the closest licensed SERM comparator — include:

• Regular monitoring of testosterone and oestradiol levels throughout treatment, as determined by the supervising specialist

• Awareness of potential adverse effects including mood changes, visual disturbances (which should prompt immediate review), and breast tissue changes

• Caution in men with hormone-sensitive conditions, a history of thromboembolic disease, or significant hepatic impairment

• Recognition that safety data for enclomiphene in men are largely extrapolated from clomifene citrate studies and limited clinical trial data; the long-term safety profile has not been established

Patients are encouraged to report any suspected adverse effects to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. Reporting helps build the post-market safety evidence base for unlicensed medicines used in the UK population and is an important patient safety tool.

Frequently Asked Questions